FDA backs Zyn nicotine pouches as lower-risk alternative, sparking health debate
The FDA approved Zyn nicotine pouches to be marketed as less hazardous than cigarettes, prompting praise from some researchers and concern from others about youth appeal and unknown long-term effects.
The FDA’s Center for Tobacco Products granted Zyn permission to advertise that switching from cigarettes to its nicotine pouches lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis. Acting director Bret Koplow said the decision provides adults with clear, science-based risk information. Supporters such as Dartmouth professor Mitch Zeller and former smoker Brian Erkkila argue the pouches are far less harmful than smoked tobacco and can aid quitting.
Opponents including Stanford pediatrician Bonnie Halpern-Felsher and Rutgers scholar Mary Hrywna caution that nicotine remains addictive, that flavors may draw adolescents, and that long-term oral health impacts are still unknown. Monitoring the Future data reveal a jump in 12th-grader lifetime use and recent use of nicotine pouches. HHS press secretary Emily Hilliard reiterated the agency’s commitment to preventing youth access, while Philip Morris International maintains its marketing targets only adults and likens a 3 mg pouch’s nicotine dose to a single cigarette.
Why it matters
It highlights a regulatory shift that could change how smokers quit and how youth are exposed to nicotine.
In this story